Engrail Therapeutics–Ysios Capital: investment, 202403 financing round Series B totalling $157m incl co-investor Ysios Capital |
2024-03-19 |
Zetta Genomics–Nina Capital: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Nina Capital |
2024-02-08 |
Zetta Genomics–Werfen: investment, 202402 2nd seed financing round expansion totalling £1.8m incl new investor We Venture Capital |
2024-02-08 |
Kynexis–Ysios Capital: investment, 202311 financing round Series A totalling €57m incl co-founding + co-investor Ysios Capital |
2023-11-07 |
SpliceBio–Optimum Strategic Communications: public relations, 202310 service existent by Optimum |
2023-10-17 |
Tagworks Pharmaceuticals–Ysios Capital: investment, 202306 financing round Series A totalling $65m incl co-lead investor Ysios Capital |
2023-06-22 |
Nuage Therapeutics–Asabys Partners: investment, 202306 seed financing round totalling €12m incl co-lead investor Asabys Partners |
2023-06-20 |
Nuage Therapeutics–Sabadell: investment, 202306 seed financing round totalling €12m incl co-investor BStartup |
2023-06-20 |
Nuage Therapeutics–SEVERAL: investment, 202306 seed financing round €12m led by Sofinnova Partners + Asabys with Innvierte + BStartup |
2023-06-20 |
Nuage Therapeutics–Sofinnova: investment, 202306 seed financing round totalling €12m incl co-lead investor Sofinnova Partners |
2023-06-20 |
Nuage Therapeutics–Spain (govt): investment, 202306 seed financing round totalling €12m incl co-investor Innvierte |
2023-06-20 |
VarmX–Ysios Capital: investment, 202305 financing round Series B2 totalling €30m incl existing + co-investor Ysios Capital |
2023-05-25 |
Oniria Therapeutics–Botín Foundation: investment, 202305 seed financing round totalling €1.28m incl lead investor Botín Foundation Mind the Gap |
2023-05-11 |
Oniria Therapeutics–Catalonia (govt): investment, 202305 seed financing round totalling €1.28m incl public funding |
2023-05-11 |
Oniria Therapeutics–Gemma Escarré Communications: public relations, 202305 service existent by GEC |
2023-05-11 |
Oniria Therapeutics–OTHER: investment, 202305 seed financing round totalling €1.28m incl business angels as co-investors |
2023-05-11 |
Oniria Therapeutics–Sabadell: investment, 202305 seed financing round totalling €1.28m incl co-investor BStartup of Banco Sabadell |
2023-05-11 |
Oniria Therapeutics–SEVERAL: investment, 202305 seed financing round €1.28m led by Botin Foundation Mind the Gap with BStartup of Banco Sabadell |
2023-05-11 |
Zetta Genomics–Nina Capital: investment, 202304 2nd seed financing round totalling £1.9m incl existing + lead investor Nina Capital |
2023-04-18 |
Adcendo–Ysios Capital: investment, 202304 financing round Series A extension totalling €31m incl existing + co-lead investor Ysios Capital |
2023-04-04 |
Sarcura–Nina Capital: investment, 202211 seed plus financing round totalling €7m incl existing + co-investor Nina Capital |
2022-11-17 |
Immucor–Werfen: investment, 202211– acquisition $2b of Immucor from TPG ANNOUNCED |
2022-11-03 |
Immunethep–EU (govt): grant, 202210– EIC Accelerator grant €2.5m to advance Paragon Novel Vaccine |
2022-10-18 |
Immunethep–EU (govt): investment, 202210– up to €12.5m equity investment from EIC Fund |
2022-10-18 |
C-mo Medical Solutions–Banco Português de Fomento: investment, 202209 seed financing round totalling €4.1m incl co-investor Portugal Ventures |
2022-09-01 |
C-mo Medical Solutions–Boehringer: investment, 202209 seed financing round totalling €4.1m incl lead investor BIVF |
2022-09-01 |
C-mo Medical Solutions–High-Tech Gründerfonds: investment, 202209 seed financing round totalling €4.1m incl co-investor HTGF |
2022-09-01 |
C-mo Medical Solutions–SEVERAL: investment, 202209 seed financing round €4.1m led by BIVF |
2022-09-01 |
Agomab Therapeutics–Asabys Partners: investment, 202207 financing round Series B extension totalling $40.5m incl new + co-investor Asabys Partners |
2022-07-13 |
Elypta–Nina Capital: investment, 202206 financing round Series A totalling $21m incl existing + co-investor Nina Capital |
2022-06-20 |
Minoryx–Columbus Venture Partners: investment, 202205 financing round Series C incl co-lead investor Columbus Venture Partners |
2022-05-31 |
Minoryx–Fund+: investment, 202205 financing round Series C incl existing + co-investor Fund+ |
2022-05-31 |
Minoryx–la Caixa: investment, 202205 financing round Series C incl existing + co-lead investor Caixa Capital Risc |
2022-05-31 |
Minoryx–SEVERAL: credit, 202205 complementary bank debt to Series C financing round (both tog totalling €51m) |
2022-05-31 |
Minoryx–SEVERAL: investment, 202205 financing round Series C (incl complementary bank totalling €51m) led by Columbus VP + Caixa Capital Risc |
2022-05-31 |
Minoryx–Spain (govt): investment, 202205 financing round Series C incl new + co-investor CDTI Innvierte |
2022-05-31 |
Minoryx–Ysios Capital: investment, 202205 financing round Series C incl existing + co-investor Ysios Capital |
2022-05-31 |
Almirall–Evotec: drug discovery services, 202205– collab multi-target RnD alliance in medical dermatology |
2022-05-19 |
Artax Biopharma–Columbus Venture Partners: investment, 202205 financing round totalling $26m incl existing investor Columbus Venture Partners |
2022-05-11 |
Ji Xing Pharmaceuticals–Hovione: ophthalmic, 202205–ww excl license to JX08 programme from Hovione to Jixing |
2022-05-09 |
Sidekick Health–Asabys Partners: investment, 202205 financing round Series B totalling $55m incl co-investor Asabys Partners |
2022-05-05 |
Integra Therapeutics–Columbus Venture Partners: investment, 202203 €1.5m addition to seed round from CLS Fund III bringing total seed round to €6m |
2022-03-29 |
SpliceBio–SEVERAL: investment, 202202 financing round Series A €50m co-led by UCB Ventures + Ysios Capital |
2022-02-16 |
GenIbet Biopharmaceuticals–Recipharm: investment, 202202 acquisition of GenIbet by Recipharm |
2022-02-01 |
Zetta Genomics–Nina Capital: investment, 202202 seed financing round totalling £2.5m incl lead investor Nina Capital |
2022-02-01 |
NorthSea Therapeutics–Ysios Capital: investment, 202112 financing round Series C totalling $80m incl new + co-lead investor Ysios Capital |
2021-12-17 |
Corteria Pharmaceuticals–Invivo Capital: investment, 202112 seed financing round totalling €12m incl co-investor Invivo Capital |
2021-12-09 |
Integra Therapeutics–Advent France Biotechnology: investment, 202112 seed financing round totalling €4.5m incl investor Advent France Biotechnology |
2021-12-02 |
Integra Therapeutics–Gemma Escarré Communications: public relations, 202112 service existent by GEC |
2021-12-02 |
Integra Therapeutics–Invivo Capital: investment, 202112 seed financing round totalling €4.5m incl investor Invivo Capital |
2021-12-02 |
Integra Therapeutics–SEVERAL: investment, 202112 seed financing round €4.5m with Advent FB + Invivo Capital + Takeda Ventures |
2021-12-02 |
Integra Therapeutics–Takeda: investment, 202112 seed financing round totalling €4.5m incl investor Takeda Ventures |
2021-12-02 |
Sanifit–Vifor Pharma: investment, 202211 acquisition 100% for €205m upfront + €170m precommercial milestones + rgoressive commercial milestones |
2021-11-22 |
Origo Biopharma–Agomab Therapeutics: investment, 202110– acquisition €na by Agomab |
2021-10-28 |
Origo Biopharma–Asabys Partners: investment, 202110 existing primary investor Asabys at time of acquisition by Agomab |
2021-10-28 |
Biotest–Grifols: investment, 202109–202204 public cash tender offer €895m for remaining 54.5% of shares at €34/ordinary share + €37/preferred share |
2021-09-17 |
Creat (CN)–Grifols: investment, 202109 acquisition 100% of Tiancheng Germany owning 90% voting rights + 45% total capital of Biotest for €773m cash |
2021-09-17 |
Nerre Therapeutics–Columbus Venture Partners: investment, 202107 financing round Series B2 totalling £20m incl new + lead investor Columbus VP |
2021-07-07 |
ViveBiotech–Image Box: public relations, 202106 service existent by Image Box Communications |
2021-06-04 |
Highlight Therapeutics–Droia Ventures: investment, 202105 existent portfolio company of Droia |
2021-05-17 |
Cytoki Pharma–Ysios Capital: investment, 202105 financing round Series A totalling $45m incl co-investor Ysios Capital |
2021-05-05 |
Adcendo–Ysios Capital: investment, 202104 financing round Series A totalling €51m incl co-lead investor Ysios Capital |
2021-04-29 |
Synendos Therapeutics–Ysios Capital: investment, 202104 investment by new investor Ysios Capital extends financing round Series A to CHF24m |
2021-04-20 |
Inbrain Neuroelectronics–SEVERAL: investment, 202103 financing round Series A €14.35m led by Asabys Partners incl follow-on from ICF VTII |
2021-03-26 |
Almirall–MC2 Therapeutics: Wynzora Cream, 202102– license excl to commercialise Wynzora Cream for plaque psoriasis in Europe for Almirall |
2021-02-17 |
MedLumics–Andera Partners: investment, 202102 financing round totalling €18m incl existing investor Andera Partners |
2021-02-10 |
MedLumics–Asabys Partners: investment, 202102 financing round totalling €18m incl new + lead investor Asabys Partners |
2021-02-10 |
MedLumics–Eurazeo: investment, 202102 financing round totalling €18m incl new investor Kurma Partners |
2021-02-10 |
MedLumics–Innogest SGR: investment, 202102 financing round totalling €18m incl existing investor Innogest Capital II |
2021-02-10 |
MedLumics–la Caixa: investment, 202102 financing round totalling €18m incl existing investor Caixa Capital Risc |
2021-02-10 |
MedLumics–Optimum Strategic Communications: public relations, 202102 service existent by Optimum |
2021-02-10 |
MedLumics–SEVERAL: investment, 202102 financing round €18m led by Asabys Partners |
2021-02-10 |
MedLumics–Spain (govt): investment, 202102 financing round totalling €18m incl new investor CDTI Innvierte Economía |
2021-02-10 |
MedLumics–VI Partners: investment, 202102 financing round totalling €18m incl new investor VI Partners Swiss Innovation |
2021-02-10 |
Minoryx–Image Box: public relations, 202101 service existent by Image Box Communications |
2021-01-26 |
CorWave–Ysios Capital: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Ysios Capital |
2021-01-06 |
Sarcura–Nina Capital: investment, 202011 seed financing round totalling €2.5m incl investor Nina Capital |
2020-11-19 |
SparingVision–Ysios Capital: investment, 202010 financing round totalling €44.5m incl new + co-investor Ysios Capital |
2020-10-21 |
Prolytic–Kymos: investment, 202009 strategic merger of Polytic GmbH + Kymos SL |
2020-09-28 |
Galecto–Ysios Capital: investment, 202009 financing round totalling $64m incl existing + co-investor Ysios Capital |
2020-09-25 |
Lava Therapeutics–Ysios Capital: investment, 202009 financing round Series C totalling $83m incl new + co-investor Ysios Capital |
2020-09-17 |
Algenex–SEVERAL: investment, 202009 private financing round €7.4m led by MasterLux + incl new investor Columbuus Life Science Fund II |
2020-09-08 |
Ona Therapeutics–Alta Life Sciences: investment, 202006 financing round Series A totalling €30m incl new investor Alta Life Sciences |
2020-06-16 |
Ona Therapeutics–Asabys Partners: investment, 202006 financing round Series A totalling €30m incl existing investor Sabadell Asabys |
2020-06-16 |
Ona Therapeutics–France (govt): investment, 202006 financing round Series A totalling €30m incl new investor Bpifrance InnoBio 2 |
2020-06-16 |
Ona Therapeutics–Fund+: investment, 202006 financing round Series A totalling €30m incl new investor Fund+ |
2020-06-16 |
Ona Therapeutics–Optimum Strategic Communications: public relations, 202006 service existent by Optimum |
2020-06-16 |
Ona Therapeutics–SEVERAL: investment, 202006 financing round Series A €30m |
2020-06-16 |
Ona Therapeutics–Ysios Capital: investment, 202006 financing round Series A totalling €30m incl new investor Ysios Capital |
2020-06-16 |
Ysios Capital–SEVERAL: investment, 202006 first closing €155m of Ysios BioFund III with target size of €200m |
2020-06-10 |
Artax Biopharma–Columbus Venture Partners: investment, 202006 financing round Series B Extension incl new + lead investor Columbus Venture Partners |
2020-06-04 |
Inbrain Neuroelectronics–SEVERAL: investment, 202006 seed financing round led by Sabadell-Asabys + Alta Life Sciences |
2020-06-01 |
Accure Therapeutics–SEVERAL: investment, 202005 financing round Series A €7.6m led by Alta Life Sciences with support from CDTI |
2020-05-26 |
FairJourney Biologics–GHO Capital: investment, 202005 investment by GHO Capital to facilitate acquisition of Iontas by FJB |
2020-05-13 |
Iontas–FairJourney Biologics: investment, 202005 acquisition of Iontas by FJB facilitaed by investment from GHO Capital |
2020-05-13 |
LNC Therapeutics–Univ Valencia: microbiomic treatment, 202004– license ww excl for patent on Christensenella therapeutics for mood disorders |
2020-04-15 |
Almirall–23andMe: therapeutic antibodies, 202001– license ww to bispecific MAb blocking all 3 isoforms of IL-36 |
2020-01-09 |
Almirall–WuXi PharmaTech: therapeutic antibodies, 202001– collab strategic RnD bispecific Abs for dermatology using WuXiBody antibody technology |
2020-01-09 |
Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve |
2020-01-08 |
Elypta–Nina Capital: investment, 201912 late seed financing round totalling €6.1m incl co-investor Nina Capital |
2019-12-01 |